Mitochondrial mortalin and cytosolic Hsp70 are essential chaperones overexpressed in cancer cells. Our goals were to reproduce our earlier findings of elevated circulating levels of mortalin and Hsp70 in colorectal cancer (CRC) patients with a larger patient cohort, to compare death risk assessment of mortalin, Hsp70, CEA and C19-9 and to assess their prognostic value in various CRC stages. Mortalin, Hsp70, CEA and CA19-9 levels were determined in sera of 235 CRC patients enrolled in the study and followed up 5 years after surgery. Association between their concentrations and patients' survival was analyzed by Kaplan-Meier estimator and subjected to Cox Proportional hazards analysis. Serum level of mortalin was independent of that of Hsp70, CEA and CA19-9, whereas Hsp70 level weakly correlated with CEA and CA19-9 levels. Improved short-term survival was found in early or advanced disease stages associated with lower mortalin and Hsp70 levels. Cox regression analysis showed a high mortality hazard (HR 5 3.7, p < 0.001) in patients with both high mortalin and Hsp70 circulating levels. Multivariate analysis showed that high mortalin and Hsp70 significantly enhances risk score over a baseline model of age, number of affected lymph nodes, CEA, CA19-9, disease stage and perioperative therapy. Analysis of mortalin and Hsp70 in CRC patients' sera adds a high prognostic value to TNM stage and to CEA and CA19-9 and identifies patients with lower or higher survival probability in all CRC stages. Determination of mortalin and Hsp70 in blood could be a useful additive prognostic tool in guiding clinical management of patients.
The heat shock proteins (HSPs) family is composed of evolutionary conserved stress proteins and chaperones that play numerous roles in cell growth, homeostasis and stress response. 1 Family members are involved in cancer proliferation, invasion and metastasis. [2] [3] [4] [5] Two of the HSPs are presented here: the cytoplasmic heat shock protein 70 (Hsp70) 6 and the mitochondrial stress 70 protein (mortalin, GRP75). [7] [8] [9] Cytoplasmic Hsp70 supports proper folding of misfolded proteins, assembly of protein complexes, protein trafficking and inhibition of death promoting proteins. 10, 11 It confers protection from various stressogenic factors and conditions such as reactive oxygen species, toxins, hypoxia, hyperthermia and others. 5 Mortalin plays a major role in import and refolding of mitochondrial proteins. [7] [8] [9] It protects cells from glucose deprivation and ROS accumulation 12 and from serum deprivation 13 and blocks apoptosis induction via p53. 14 It also promotes tumorigenesis. 15 In contrast, knock down of mortalin caused senescence-like growth arrest in immortalized cells. 16 The main cellular location of mortalin is in mitochondria, yet it was described also in other cellular compartments. 17 Hsp70 18 and mortalin 19, 20 play a role in protection of cancer cells from complement-dependent cytotoxicity. Following complement attack, both Hsp70 18 and mortalin 19 appear on the surface of the targeted cells. Under nonlytic conditions, mortalin relocates rapidly from mitochondria to the cell surface 21 and is also shed out from the cells. 19, 20, 22 Release of cytosolic Hsp70 from cells is a wellknown phenomenon. 23 Cytoplasmic Hsp70 is overexpressed in cancer and this is correlated with accelerated proliferation, aggressiveness and chemoresistance. 2, 24, 25 Thus, elevated expression of Hsp70 is a marker for advanced disease and poor prognosis in colon cancer, breast cancer, melanoma and bladder cancer. 4, 5 In a prospective study, baseline serum concentration of soluble Hsp70 was associated with an increased risk of lung cancer. 26 Plasma level of soluble Hsp70 was found to be a potential biomarker for small-cell lung cancer and prostate cancer, although its clinical utility is still undefined. 27,28 Extracellular soluble Hsp70 was also identified in blood plasma of patients with colorectal cancer, 29 and was found to be a stageindependent prognostic marker in colorectal cancer, especially in patients without distant metastasis. These findings were reproduced recently with a larger group of CRC patients (Gr af et al. manuscript in preparation).
Mortalin is also overexpressed in cancer. 15, 30 Thus, in human colorectal adenocarcinoma, higher mortalin expression in the cancer cells correlates with poor patient survival. 31 Elevated expression of mortalin in gastric cancer is associated with deeper invasion and more metastases. 32 In our earlier study performed on 175 colorectal carcinoma (CRC) patients, a higher concentration of soluble mortalin in blood serum was found to correlate with shorter patients' survival. 33 Serum levels of mortalin and cytosolic Hsp70 were found to be independent variables in these patients. Concurrence of high mortalin and high Hsp70 in the CRC patients' sera was associated with a rapid mortality. 33 Here, this study was repeated with a larger cohort of independent CRC patients and extended to include measurements of CEA and CA19-9 levels. As shown here, serum levels of mortalin, CEA and CA19-9 vary in patients independently. CRC patients with high mortalin and high Hsp70 in their serum have a poor prognosis, irrespective of their cancer stage. Importantly, multivariate analysis indicated that determination of mortalin and Hsp70 levels in CRC patients' sera is adding a high prognostic value to the TNM stage and the levels of CEA and CA19-9.
MATERIAL AND METHODS
Patients, pathology and serum samples Table 1 . After diagnosis and adequate surgery, patients were treated and followed in the oncology ward according to the stage of their disease and to the current guidelines. Patients with locally advanced rectal cancer (cT3 or N1 disease) received radiochemotherapy before definitive surgery. Patients who were offered postoperative chemotherapy by a multidisciplinary tumor board decision received 6 month adjuvant chemotherapy starting 4-6 weeks after surgery. Twenty-two patients who had unresectable and/or metastatic disease received upfront primary systemic treatment without definitive surgery. Lymphovascular and/or venous invasion (LVI) and perineural invasion (PNI) were assessed by a qualified pathologist and included in the routine pathological report. Vascular invasion was regarded positive when tumor cells were detected in the lumen of any peritumoral vein or lymphatic vessel. These indicative findings are referred together as LVI. PNI was indicated as positive when tumor cells were seen in circular fashion around any peritumoral nerve. During follow-up of at least 5 years, overall survival data were collected.
Mortalin and Hsp70 ELISA
The capture ELISA used for measuring serum levels of mortalin was described earlier. 33 Briefly, microtiter plate wells (Thermo Fisher Scientific, Rochester, NY) were coated overnight at 48C with 1 mg/ml mouse monoclonal antibody directed to human mortalin (Abcam) in TB (50 mM Tris Base pH 7.0, 100 mM NaCl). Following blocking of the wells with bovine serum albumin in TBS for 1 hr at 378C, diluted CRC patients' serum samples (diluted 1:3 in Tris buffer
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saline) were added to the wells. Next, the wells were washed with TBT (TB with 0.05% Tween-20) and treated with a goat anti-mortalin polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) diluted in TB for 1 hr at 378C. Finally, after a wash with TBT, peroxidase-conjugated donkey anti-goat IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) diluted in TB was added for 1 hr at 258C. Antibody binding was quantified by using TMB One Component Microwell Substrate (SouthernBiotech, Birmingham, AL) and absorbance was read at 450 nm in a Microplate Reader (Spectrafluor plus, Tecan, Austria). In each ELISA test plate, a linear calibration of increasing mortalin concentrations was performed with normal human serum supplemented with 0-10 ng recombinant mortalin. 34 Normal human serum without added mortalin gave no signal above background controls. Furthermore, the signal observed with normal human serum was not affected by preadsorption of the serum over an affinity column bearing antimortalin antibodies. Soluble Hsp70 levels in the serum were measured using the ELISA kit of R&D Systems (Minneapolis, MN), according to the manufacturer's instructions as described earlier. 29 Serum Hsp70 levels in healthy individuals (median, 25-75 percentile) were determined in our two earlier studies. Young (nonpregnant) women had 0.29 (0.20-0.35) ng/ml serum Hsp70 35 and healthy adults had 0.59 (0.43-0.89) ng/ml serum Hsp70. 36 
Statistical analysis
Statistical analysis was performed using the SPSS 15.0 software (SPSS Inc., Chicago, IL). Patients' survival was tested by the Kaplan-Meier survival analysis, using the Log Rank test. The impact of various variables on patients' survival was tested by the Cox proportional hazards analysis (univariate and multivariate analyses). The results of the Cox regression models are presented as hazard ratios, the corresponding 95% confidence intervals (CI) and the Wald v 2 and p values of likelihood ratio tests.
RESULTS
The levels of mortalin were determined in the sera of the patients. Mortalin concentration varied in the sera of this cohort of CRC patients between 0 and 7,753 ng/ml with a median value of 30 ng/ml. Hsp70, CEA and CA19-9 levels were determined in our recent study (Gr af et al. manuscript in preparation). Spearman's rank correlation coefficient analysis showed that serum levels of mortalin in the patients did not correlate with the Hsp70, CEA and CA19-9 levels (Supporting Information, Table S1 ). Serum levels of Hsp70 (median value 1.65 ng/ml) showed modest, but significant correlation with CEA (r 5 0.19; p 5 0.005) and CA19-9 (r 5 0.21; p 5 0.002) levels. CEA and CA19-9 showed a good correlation (r 5 0.48; p < 0.001) in these patients. The v 2 d distribution of serum Hsp70 and mortalin levels among CRC stages I-IV was also examined. A weak correlation was observed between Hsp70 levels and CRC stages (p 5 0.013) and no correlation between mortalin levels and CRC stages (p 5 0.236) (Supporting Information, Table S2 ).
Records of lymphatic vascular invasion (LVI) and perineural invasion (PNI) were also analyzed. By using the Mann-Whitney U test, the distribution of circulating Hsp70 and mortalin levels were compared between patients with negative and positive LVI or PNI. No correlation was found between Hsp70 levels (p 5 0.065; p 5 0.353) or mortalin levels (p 5 0.844; p 5 0.660) and LVI or PNI (respectively).
Kaplan-Meier survival analysis of the patients in stage I, stage II, stage III and stage IV (Fig. 1a) showed the clear (Fig. 1b) . In the Kaplan-Meier survival analysis shown in Figure 1c , the patients were divided into 4 groups according to mortalin and Hsp70 levels: patients with low mortalin and Hsp70 (low/low), patients with low mortalin and high Hsp70 (low/high), patients with high mortalin and low Hsp70 (high/low) and patients with high mortalin and Hsp70 (high/high). Survival of the low/low patients was much better than the low/high (p 5 0.002), high/ low (p 5 0.01) and high/high (p < 0.001) patients. Cox regression analysis of the 4 subgroups of patients according to mortalin and Hsp70 also supported the observation that having high Hsp70 and/or mortalin (>median values) is associated with faster disease progression (Table 2) . Thus, high/high patients had a hazard of 3.7 (95% CI 1.85-7.35, p < 0.001) relative to low/low patients.
Subdividing the patients according to their stages (Fig. 2 ) showed that having a high/high mortalin/Hsp70 phenotype was a worse prognosis for all. Regarding early stages, 3 stage I/II CRC patients with high mortalin and high Hsp70 (out of 15 patients with high/high phenotype) survived less than a year despite surgery and conventional therapy, whereas all patients with low mortalin and low Hsp70 (26 patients with low/low phenotype) survived at least 2 years ( Fig. 2 and Supporting Information, Table S3 ). In stage III patients, after 6 years, 100% of low/low patients survived but only 52% of the patients who had either high mortalin or Hsp70 or both survived. In stage IV patients, after 6 years, 40% of low/low patients survived but only 8% of the patients who had either high mortalin or Hsp70 or both survived. Univariate analysis by Cox regression of the variables of the patients: sex, age, grade and stage of the disease and serum CEA, CA19_9, mortalin and Hsp70 concentrations are presented in Table 3 . Only patients without missing data were included in this analysis (n 5 207-231). Age was found to be a highly significant factor with a hazard of 1.04 (p < 0.001). High Hsp70 serum concentration (>1.65 ng/ml) was associated with mortality with an HR of 1.92 (p < 0.001). High mortalin level (>30 ng/ml) was also found to be a significant factor (p 5 0.04) with a hazard ratio of 1.53.
Multivariate analysis of the risk of mortality was performed on 185 patients for whom all information was available. The added value of high Hsp70 and high mortalin to a baseline model of age, CEA, CA19-9, TNM staging and systemic perioperative therapy was analyzed. It significantly (p < 0.001) increased the hazard ratio to 4.8 (95% CI 2.10-11.18) ( Table 4) . We conclude that analysis of mortalin and Hsp70 in CRC patients' sera adds a high prognostic value to the TNM staging and to the levels of CEA and CA19-9 and will identify colorectal cancer patients at low risk as well as high risk of short survival. Patients divided according to their mortalin (low: 30 ng/ml, high: >30 ng/ml) and Hsp70 (low: 1.65 ng/ml, high: >1.65 ng/ml) levels. Patients subdivided into low/low (blue), high/low (green), low/high (beige) and high/high (purple) levels of mortalin/Hsp70 levels in their sera. Number of patients (survivors/all) and significance of difference between survival curves of high/high and low/low patients are shown. 
DISCUSSION
Colorectal cancer patients were shown to have circulating soluble mortalin and Hsp70 in their blood. 29, 33 In earlier studies, we demonstrated that patients with high levels of Hsp70 and/or mortalin are at risk of shorter survival. 33 The results shown here reinforce this claim in a second larger cohort of colorectal patients and compares their prognostic strength with that of tumor stage, grade and traditional tumor markers such as CEA and CA19-9. Importantly, the concentrations of Hsp70, CEA and CA19-9 distributed differently from mortalin in patients' sera, thus allowing testing of prognosis based on their combined expression. Univariate Cox regression analysis confirmed that the four variables were significant prognostic markers of mortality.
To detect Hsp70, this study utilized an assay that was optimized and validated for the detection of free, circulating Hsp70. 29 More recently, a novel assay was developed to detect both free Hsp70 and Hsp70 bound to lipid vesicles (lipHsp70 ELISA). 37 It will be interesting to examine if the findings reported here may be reproduced with a novel lipHsp70 ELISA. The latter assay was recently used to show in non-small-cell lung cancer patients a positive correlation between tumor volume and serum Hsp70. 38 Tumor volume was not measured in the CRC patients described here, but lymphatic vascular invasion and perineural invasion were recorded. No correlation was found between Hsp70 or mortalin levels and the extent of LVI or PNI.
Survival curves clearly demonstrated that above-median concentrations of either mortalin or Hsp70 categorize colorectal cancer patients as patients at risk of shorter survival. This is even more pronounced when both mortalin and Hsp70 are elevated. Strikingly, percentage of surviving patients after 4 years was 50% in the high/high patients group and 80% in the low/low patients group. Analysis of the added value of measurements of mortalin and Hsp70 concentrations in blood serum on top of the clinical value of the conventional tests extensively performed in the clinics (Table 4) is demonstrating unequivocally that identification of patients with high Hsp70 and high mortalin is essential as their risk of mortality is much increased (HR5 4.84, 2.10-11.18, p < 0.001).
An important conclusion from our findings (Fig. 2) is that determinations of mortalin and Hsp70 concentrations in blood may be an extremely valuable noninvasive test for assessment and management of both early stage and advanced stage colorectal cancer patients. Kaplan-Meier curves (Fig. 2) and Cox regression analyses (not shown) of survival of early stage patients clearly demonstrate that stages I and II patients with the high/high phenotype should be regarded as high risk and may require adjuvant treatment, similar to stage III and stage IV traditionally high-risk patients. In our last cohort of CRC patients, 3 out of 15 patients with high/high phenotype died within 3 years. In contrast, for stages III and IV CRC patients, having a low/low mortalin/Hsp70 phenotype is clearly indicative of longer survival times. Thus, 5 years after their operation, all 17 "low/low" stage III CRC patients were alive, whereas 25 of the other 48 stage III patients have died. Collectively, the findings presented in this article and our earlier report 33 strongly indicate that measurements of mortalin and Hsp70 levels in serum of CRC patients have an important added value for clinical management of these patients.
It still remains to be tested whether or not high mortalin and/or high Hsp70 in serum are predictive markers to one or more of the prevailing therapeutic strategies. As CRC is a prevalent cause of death from cancer, the impact of any novel and effective predictive marker will likely have a major impact on cancer death. Clearly, 39 this is a priority area for future research on CRC and on cancer at large. Several circulating proteins have been proposed as diagnostic, predictive and prognostic biomarkers for CRC, including CEA, CA19-9, p53 and VEGF. [39] [40] [41] [42] We propose that for the benefit of successful precision cancer therapy, mortalin and Hsp70 should be considered and examined as predictive biomarkers to assess success of conventional, targeted-and immunotherapies in early and advanced metastatic CRC. This will enable identification beforehand of patients who are going to benefit from each therapy. The source for circulating mortalin and Hsp70 is still not clear. They are known to be released in vitro from cells undergoing stress. In the cancer patients, they may originate from the cancer cells and/or from affected organs and tissues. Future research will have to determine whether, besides being biomarkers, circulating mortalin and Hsp70 have any impact on tumor progression and through which mechanism. Nowadays, cellular chaperones are considered major targets for cancer therapy and numerous targeted therapies are under development. 4, 11 Treatment modalities targeting the chaperones at the protein level will have to take into account the circulating levels of these chaperones that will likely affect their therapeutic efficacy.
